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Tuberculosis (TB) currently represents a major global
health concern, especially when considering the emer-
gence of multidrug-resistant strains of Mycobacterium
tuberculosis. On this regard, the identification of new
effective agents to treat this infectious disease is urgently
needed. Herein, we describe the pre-clinical assays on the
anti-tubercular effects of a pentacyano(isoniazid)ferrate(II)
compound, namely IQG-607. Previous experimental evi-
dence [1] clearly demonstrated the in vivo effectiveness of
this compound in a mouse model of TB infection. Accord-
ingly, IQG-607 (22 to and 560 µmol/kg) was able to mark-
edly reduce the number of colony-forming units (CFU) in
both spleen and lungs of M. tuberculosis H37Rv-infected
animals, following long-term schemes of oral administra-
tion, during 28 or 56 days. In this series of experiments,
the effects of IQG-607 were comparable to those observed
for the reference compound isoniazid (182 µmol/kg).
More recently, we demonstrated that in vitro incubation
of IQG-607 led to a marked reduction of CFU counts in
M. tuberculosis H37Rv-infected macrophages, being this
effect similar to that displayed by either isoniazid or rifam-
picin [2]. Concerning the mechanism of action, IQG-607
was found able to block the biosynthesis of mycolic acids,
as indicated by radiolabelling studies with acetate incor-
poration [2], and it displayed bactericidal effects when
tested in vivo [1]. The acute oral administration of IQG-
607 (560 to 1120 µmol/kg) was not related to any clinical
sign of toxicity, whereas the treatment with isoniazid
(182 µmol/kg) led to death rates of 80% in mice [3]. The
same doses of IQG-607 were also devoid of toxicity, when
administered acutely by oral route to rats (unpublished
data). To extend evidence on the safety profile of IQG-
607, this molecule was also examined in a protocol of
repeated dose 90-day oral toxicity in rats. As a main con-
clusion, there was no evidence of severe toxic signals,
although it was not possible to accurately define the
NOAEL (non-toxic adverse effect level) for IQG-607.
Nevertheless, the dose of 56 µmol/kg might be assumed,
once the animals treated with this dose did not show any
signal of toxicity (unpublished data). Taken together, our
results provide convincing evidence on the efficacy of
IQG-607. It can be assumed that IQG-607 is well
absorbed when dosed by oral route, being able to reach
the bacilli and killing them within the phagosome of the
macrophages. Furthermore, we demonstrated a favorable
toxicological outcome for this compound, even when
dosed acutely, or in long-term schedules of administration,
for both mice and rats. Further studies are required to
determine the safety of IQG-607 in non-rodent species, as
well as the efficacy of this molecule against resistant
strains of M. tuberculosis. Although additional experi-
ments with this molecule are still required, it is tempting
to infer that IQG-607 might well represent a lead com-
pound for development of innovative anti-TB drugs.
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